Skip to main content
Contact Us
Subscribe
E-Edition
59°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bioxcel Therapeutics Inc
(NQ:
BTAI
)
0.5265
+0.0115 (+2.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bioxcel Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
May 25, 2023
Via
Benzinga
Why Dollar Tree Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
May 25, 2023
Gainers Beamr Imaging Ltd. (NASDAQ: BMR) shares climbed 211.6% to $6.86 after NVIDIA announced the release of NVENC Video Codec SDK 12.1 showcasing the integration with Beamr CABR.
Via
Benzinga
Why Shares of BioXcel Therapeutics Are Dropping Thursday
May 25, 2023
A trial for one of the company's therapies didn't meet its primary endpoint.
Via
The Motley Fool
Looking Into BioXcel Therapeutics's Return On Capital Employed
May 22, 2023
Via
Benzinga
The Latest Analyst Ratings for BioXcel Therapeutics
May 09, 2023
Via
Benzinga
Why BioXcel Therapeutics Stock Marched Higher Today
May 08, 2023
The biotech's Q1 earnings report set the stage for a flurry of important clinical updates in the coming months.
Via
The Motley Fool
BioXcel Therapeutics Stock Tumbles: Company Releases Mixed Results From Lower Dose Igalmi Study In Bipolar/Schizophrenia Associated Agitation
May 25, 2023
Via
Benzinga
BioXcel Stock Crashes 22% As Bid To Double Its Market Appears Less Certain
May 25, 2023
The company is hoping to double its market opportunity. But that looks less certain.
Via
Investor's Business Daily
BioXcel Therapeutics Reports Encouraging Phase 1b Results For Innovative Depression Treatment
May 16, 2023
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced topline data from its Phase 1b multiple ascending dose (MAD) trial of BXCL501 (dexmedetomidine) sublingual film, for agitation associated with...
Via
Benzinga
Why These 3 Nasdaq Stocks Were Glowing Green This Week
May 11, 2023
These three biopharmaceutical stocks rocketed higher this week.
Via
The Motley Fool
BioXcel Earnings Miss Q1 Estimates Due To Higher Costs, Expects Uptick In Revenues
May 08, 2023
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) reported first-quarter FY23 revenues of $206,000,
Via
Benzinga
Axsome Surges As Its Newest Product Shines. But BioXcel Does The Opposite.
May 08, 2023
Axsome shares are nearing a breakout point. But BioXcel crumbled on its report.
Via
Investor's Business Daily
BioXcel Therapeutics's Earnings Outlook
May 05, 2023
Via
Benzinga
6 Analysts Have This to Say About BioXcel Therapeutics
March 10, 2023
Via
Benzinga
Earnings Preview: BioXcel Therapeutics
March 08, 2023
Via
Benzinga
Expert Ratings for BioXcel Therapeutics
February 08, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 08, 2023
Via
Benzinga
The Next Evolution In Drugs? It's Artificial Intelligence, Says This CEO
May 04, 2023
This company is hoping to execute for a second time on its moonshot goal.
Via
Investor's Business Daily
Meta Platforms To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Tuesday
March 21, 2023
Morgan Stanley boosted the price target for HubSpot, Inc. (NYSE: HUBS) from $447 to $466. Morgan Stanley analyst Keith Weiss maintained an Overweight rating. HubSpot shares fell 1.9% to close at...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
March 10, 2023
Via
Benzinga
Why BioXCel Therapeutics Stock Jumped This Week
December 15, 2022
A couple of analysts recently upgraded their views on the biotech stock.
Via
The Motley Fool
Analyst Ratings for BioXcel Therapeutics
December 01, 2022
Via
Benzinga
BioXcel Therapeutics Unveils Complete Data From BXCL701/Keytruda Combo Study In Prostate Cancer Subtype
February 14, 2023
Via
Benzinga
Analyst Reiterates This Alzheimer's Candidate As Top Idea For 2023
February 08, 2023
Via
Benzinga
ChatGPT Is Just The 'Tip Of The Iceberg' In Content-Creating Artificial Intelligence; Get Ready For 'A Lot Of Disruption' (Not Just At Google)
February 03, 2023
"A lot of disruption" may be coming soon to a host of industries. Google may be at risk.
Via
Investor's Business Daily
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
Is This Soaring Growth Stock a Buy?
November 20, 2022
The answer may depend on your risk tolerance.
Via
The Motley Fool
2 Beaten-Down Stocks to Watch Closely Next Year
December 06, 2022
These biotechs could skyrocket in 2023, but only if they can execute their plans.
Via
The Motley Fool
Why BioXcel Therapeutics Stock Triumphed This Week
December 02, 2022
An analyst feels that the best is shortly to come for the company.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
December 01, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.